Combination of Pharmacophore Matching, 2D Similarity Search, and In Vitro Biological Assays in the Selection of Potential 5‐HT6 Antagonists from Large Commercial Repositories
暂无分享,去创建一个
Beáta Flachner | István Simon | Csaba Magyar | Ferenc Fülöp | György Dormán | Krisztina Dobi | István Hajdú | Mária Szaszkó | Melinda Bognár | Zsolt Lőrincz | I. Simon | C. Magyar | I. Hajdú | B. Flachner | Z. Lorincz | S. Cseh | G. Dormán | F. Fülöp | Mária Pukáncsik | Krisztina Dobi | Mária Pukáncsik | Enikő Máthé | Melinda Bognár | Mária Szaszkó | Enikő Máthé | Sándor Cseh
[1] H. Greiner,et al. 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. , 2005, Bioorganic & medicinal chemistry letters.
[2] S. L. Dixon,et al. The hidden component of size in two-dimensional fragment descriptors: side effects on sampling in bioactive libraries. , 1999, Journal of medicinal chemistry.
[3] David E. Shaw,et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..
[4] C. Marsden,et al. 5-ht6 receptors. , 2004, Current drug targets. CNS and neurological disorders.
[5] G. Martin,et al. Classification and nomenclature of 5-HT receptors: a comment on current issues , 1995, Behavioural Brain Research.
[6] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[7] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[8] D. Sibley,et al. Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.
[9] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[10] G. Keserű,et al. Integration of virtual and high throughput screening in lead discovery settings. , 2011, Combinatorial chemistry & high throughput screening.
[11] Sean L Kitson,et al. 5-hydroxytryptamine (5-HT) receptor ligands. , 2007, Current pharmaceutical design.
[12] V. Madison,et al. Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model. , 2008, Journal of medicinal chemistry.
[13] C. Abad-Zapatero,et al. Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.
[14] Robert C. Glen,et al. Similarity Metrics and Descriptor Spaces — Which Combinations to Choose , 2007 .
[15] Y Z Chen,et al. Virtual screening methods as tools for drug lead discovery from large chemical libraries. , 2012, Current medicinal chemistry.
[16] Peter Willett,et al. Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.
[17] Li Di,et al. Drug-like property concepts in pharmaceutical design. , 2009, Current pharmaceutical design.
[18] Leonardo Pardo,et al. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. , 2005, Journal of medicinal chemistry.
[19] A. Brown,et al. 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. , 1999, Journal of medicinal chemistry.
[20] P P Humphrey,et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.
[21] J. Bockaert,et al. 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. , 1994, Neuroreport.
[22] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[23] G. Savettieri,et al. Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson’s disease , 2002, Neurology.
[24] 6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6 receptor antagonists. , 2000, Bioorganic & medicinal chemistry letters.
[25] M. R. Akl,et al. Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors. , 2014, European journal of medicinal chemistry.
[26] S. Rees,et al. A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. , 1997, Analytical biochemistry.
[27] Anna Gulyás-Forró,et al. Design, Selection, and Evaluation of a General Kinase‐Focused Library , 2009, ChemMedChem.
[28] A. Robichaud,et al. 5‐HT6 antagonists as potential treatment for cognitive dysfunction , 2009 .
[29] P. Willett,et al. A Comparison of Some Measures for the Determination of Inter‐Molecular Structural Similarity Measures of Inter‐Molecular Structural Similarity , 1986 .
[30] Tudor I. Oprea,et al. Strategies for compound selection. , 2004, Current drug discovery technologies.
[31] X. Codony,et al. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. , 2008, Pharmacology & therapeutics.
[32] Andrzej J Bojarski,et al. Pharmacophore models for metabotropic 5-HT receptor ligands. , 2006, Current topics in medicinal chemistry.
[33] R Marsault,et al. Transfected Aequorin in the Measurement of Cytosolic Ca2+ Concentration ([Ca2+]c) , 1995, The Journal of Biological Chemistry.
[34] M. Garcia-Alloza,et al. Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease , 2004, Neuropsychopharmacology.
[35] Leonardo Pardo,et al. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. , 2014, Journal of medicinal chemistry.
[36] Marvin Johnson,et al. Concepts and applications of molecular similarity , 1990 .
[37] J. Holenz,et al. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. , 2006, Drug discovery today.
[38] Varun Khanna,et al. Physiochemical property space distribution among human metabolites, drugs and toxins , 2009, BMC Bioinformatics.
[39] D. Bennett,et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.
[40] Robert C. Glen,et al. Similarity Metrics and Descriptor Spaces – Which Combinations to Choose? , 2006 .
[41] Hongma Sun,et al. Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.
[42] Björn Krüger,et al. The holistic integration of virtual screening in drug discovery. , 2013, Drug discovery today.
[43] A. Hopkins,et al. The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.
[44] W. L. Jorgensen. The Many Roles of Computation in Drug Discovery , 2004, Science.
[45] G. Bernardi,et al. Endogenous Serotonin Excites Striatal Cholinergic Interneurons via the Activation of 5-HT 2C, 5-HT6, and 5-HT7 Serotonin Receptors: Implications for Extrapyramidal Side Effects of Serotonin Reuptake Inhibitors , 2007, Neuropsychopharmacology.
[46] P. Bonaventure,et al. Recent Advances on the 5-HT5A, 5-HT6 and 5-HT7 Receptors , 2008 .
[47] I. Hajdú,et al. Rapid in silico selection of an MCHR1 antagonists’ focused library from multi-million compounds’ repositories: biological evaluation , 2014, Medicinal Chemistry Research.
[48] Claire Mount,et al. Alzheimer disease: progress or profit? , 2006, Nature Medicine.
[49] S. Tkachenko,et al. Synthesis and structure-activity relationship (SAR) of (5,7-disubstituted 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methylamines as potent serotonin 5-HT(6) receptor (5-HT(6)R) antagonists. , 2011, Journal of medicinal chemistry.
[50] Beáta Flachner,et al. Combination of 2D/3D Ligand-Based Similarity Search in Rapid Virtual Screening from Multimillion Compound Repositories. Selection and Biological Evaluation of Potential PDE4 and PDE5 Inhibitors , 2014, Molecules.
[51] Richard Morphy,et al. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.
[52] Jürgen Bajorath,et al. Comparison of 2D Fingerprint Methods for Multiple‐Template Similarity Searching on Compound Activity Classes of Increasing Structural Diversity , 2007, ChemMedChem.
[53] György Dormán,et al. Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds’ repositories: biological evaluation , 2011, Molecular Diversity.
[54] Sheng-Yong Yang,et al. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.
[55] M. Brownstein,et al. Aequorin-expressing mammalian cell lines used to report Ca2+ mobilization. , 1993, Cell calcium.
[56] S. Nawoschik,et al. Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. , 2003, European journal of pharmacology.
[57] Jürgen Bajorath,et al. Virtual screening methods that complement HTS. , 2004, Combinatorial chemistry & high throughput screening.